Literature DB >> 29222237

The role of targeted therapy in the management of patients with AML.

Alexander E Perl1.   

Abstract

Drug therapy for acute myeloid leukemia (AML) is finally undergoing major changes in 2017. This is due to the US Food and Drug Administration's approval of several new, targeted agents (midostaurin, enasidenib, and gemtuzumab ozogamicin). Paired with the recent approval of a novel liposomal formulation of daunorubicin/cytarabine (CPX-351/Vyxeos), the standard of care is changing rapidly in AML for subgroups. This review will focus on currently approved agents and promising novel agents in development and will highlight controversial areas in targeted treatment.
© 2016 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29222237      PMCID： PMC6142552          DOI： 10.1182/asheducation-2017.1.54

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN： 1520-4383


  59 in total

1.  Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.

Authors:  Arthur E Frankel; Jung H Woo; Chul Ahn; Naveen Pemmaraju; Bruno C Medeiros; Hetty E Carraway; Olga Frankfurt; Stephen J Forman; Xuezhong A Yang; Marina Konopleva; Francine Garnache-Ottou; Fanny Angelot-Delettre; Christopher Brooks; Michael Szarek; Eric Rowinsky
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

2.  Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.

Authors:  Catherine C Smith; Chao Zhang; Kimberly C Lin; Elisabeth A Lasater; Ying Zhang; Evan Massi; Lauren E Damon; Matthew Pendleton; Ali Bashir; Robert Sebra; Alexander Perl; Andrew Kasarskis; Rafe Shellooe; Garson Tsang; Heidi Carias; Ben Powell; Elizabeth A Burton; Bernice Matusow; Jiazhong Zhang; Wayne Spevak; Prabha N Ibrahim; Mai H Le; Henry H Hsu; Gaston Habets; Brian L West; Gideon Bollag; Neil P Shah
Journal:  Cancer Discov       Date:  2015-04-06       Impact factor: 39.397

3.  Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.

Authors:  Yasmin Abaza; Hagop Kantarjian; Guillermo Garcia-Manero; Elihu Estey; Gautam Borthakur; Elias Jabbour; Stefan Faderl; Susan O'Brien; William Wierda; Sherry Pierce; Mark Brandt; Deborah McCue; Rajyalakshmi Luthra; Keyur Patel; Steven Kornblau; Tapan Kadia; Naval Daver; Courtney DiNardo; Nitin Jain; Srdan Verstovsek; Alessandra Ferrajoli; Michael Andreeff; Marina Konopleva; Zeev Estrov; Maria Foudray; David McCue; Jorge Cortes; Farhad Ravandi
Journal:  Blood       Date:  2016-12-21       Impact factor: 22.113

4.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

5.  Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.

Authors:  June M McKoy; Cara Angelotta; Charles L Bennett; Martin S Tallman; Martha Wadleigh; Andrew M Evens; Timothy M Kuzel; Steve M Trifilio; Dennis W Raisch; Jonathan Kell; Daniel J DeAngelo; Francis J Giles
Journal:  Leuk Res       Date:  2006-09-07       Impact factor: 3.156

6.  Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.

Authors:  Susan O'Brien; Joseph O Moore; Thomas E Boyd; Loree M Larratt; Aleksander Skotnicki; Benjamin Koziner; Asher A Chanan-Khan; John F Seymour; R Gregory Bociek; Steve Pavletic; Kanti R Rai
Journal:  J Clin Oncol       Date:  2007-02-12       Impact factor: 44.544

Review 7.  FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.

Authors:  Michael R Grunwald; Mark J Levis
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

8.  FLT3 inhibitor-induced neutrophilic dermatosis.

Authors:  Amir T Fathi; Long Le; Robert P Hasserjian; Hossein Sadrzadeh; Mark Levis; Yi-Bin Chen
Journal:  Blood       Date:  2013-05-17       Impact factor: 22.113

9.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Authors:  Eytan M Stein; Courtney D DiNardo; Daniel A Pollyea; Amir T Fathi; Gail J Roboz; Jessica K Altman; Richard M Stone; Daniel J DeAngelo; Ross L Levine; Ian W Flinn; Hagop M Kantarjian; Robert Collins; Manish R Patel; Arthur E Frankel; Anthony Stein; Mikkael A Sekeres; Ronan T Swords; Bruno C Medeiros; Christophe Willekens; Paresh Vyas; Alessandra Tosolini; Qiang Xu; Robert D Knight; Katharine E Yen; Sam Agresta; Stephane de Botton; Martin S Tallman
Journal:  Blood       Date:  2017-06-06       Impact factor: 25.476

10.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Authors:  Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson
Journal:  Cancer Cell       Date:  2010-02-18       Impact factor: 38.585
View more
  14 in total

1.  Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.

Authors:  Jonas Samuel Jutzi; Titiksha Basu; Maximilian Pellmann; Sandra Kaiser; Doris Steinemann; Mathijs A Sanders; Adil S A Hinai; Annelieke Zeilemaker; Sarolta Bojtine Kovacs; Christoph Koellerer; Jenny Ostendorp; Konrad Aumann; Wei Wang; Emmanuel Raffoux; Bruno Cassinat; Lars Bullinger; Brigitte Schlegelberger; Peter J M Valk; Heike Luise Pahl
Journal:  Blood       Date:  2019-02-12       Impact factor: 22.113

Review 2.  Precision Medicine in Myeloid Malignancies: Hype or Hope?

Authors:  Shristi Upadhyay Banskota; Nabin Khanal; Rosalyn I Marar; Prajwal Dhakal; Vijaya Raj Bhatt
Journal:  Curr Hematol Malig Rep       Date:  2022-08-16       Impact factor: 4.213

3.  Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia.

Authors:  Zi-Jun Xu; Xin-Long Zhang; Ye Jin; Shi-Sen Wang; Yu Gu; Ji-Chun Ma; Xiang-Mei Wen; Jia-Yan Leng; Zhen-Wei Mao; Jiang Lin; Jun Qian
Journal:  Mol Ther Oncolytics       Date:  2022-06-06       Impact factor: 6.311

Review 4.  Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML.

Authors:  Anne Sophie Kubasch; Uwe Platzbecker
Journal:  Cancers (Basel)       Date:  2018-05-24       Impact factor: 6.639

Review 5.  Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow.

Authors:  Raoufeh Ahamadi-Fesharaki; Abolfazl Fateh; Farzam Vaziri; Ghasem Solgi; Seyed Davar Siadat; Fereidoun Mahboudi; Fatemeh Rahimi-Jamnani
Journal:  Mol Ther Oncolytics       Date:  2019-03-23       Impact factor: 7.200

6.  Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo.

Authors:  Nicole D Vincelette; Husheng Ding; Amelia M Huehls; Karen S Flatten; Rebecca L Kelly; Mira A Kohorst; Jonathan Webster; Allan D Hess; Keith W Pratz; Larry M Karnitz; Scott H Kaufmann
Journal:  Sci Rep       Date:  2019-03-05       Impact factor: 4.379

7.  Leveraging Single-Cell RNA Sequencing Experiments to Model Intratumor Heterogeneity.

Authors:  Meghan C Ferrall-Fairbanks; Markus Ball; Eric Padron; Philipp M Altrock
Journal:  JCO Clin Cancer Inform       Date:  2019-04

Review 8.  Advances in targeted therapy for acute myeloid leukemia.

Authors:  Jifeng Yu; Peter Y Z Jiang; Hao Sun; Xia Zhang; Zhongxing Jiang; Yingmei Li; Yongping Song
Journal:  Biomark Res       Date:  2020-05-20

9.  Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.

Authors:  Yann Ferret; Nicolas Boissel; Nathalie Helevaut; Jordan Madic; Olivier Nibourel; Alice Marceau-Renaut; Maxime Bucci; Sandrine Geffroy; Karine Celli-Lebras; Sylvie Castaigne; Xavier Thomas; Christine Terré; Hervé Dombret; Claude Preudhomme; Aline Renneville
Journal:  Haematologica       Date:  2018-02-22       Impact factor: 11.047

Review 10.  Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

Authors:  Wei Shi; Weiwei Jin; Linghui Xia; Yu Hu
Journal:  Acta Pharm Sin B       Date:  2020-06-30       Impact factor: 11.413
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.